BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors

被引：58
|
作者：
Vlasceanu, Alexandru [3 ]
Jessing, Mikkel [1 ,2 ]
Kilburn, John Paul [1 ,2 ]
机构：
[1] H Lundbeck & Co AS, Discovery Chem, DK-2500 Valby, Denmark
[2] H Lundbeck & Co AS, DMPK, DK-2500 Valby, Denmark
[3] Univ Copenhagen, Dept Chem, DK-2100 Copenhagen, Denmark
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2015年 / 23卷 / 15期
关键词：
Borazaronaphthalenes; PDE10A inhibitors; Antipsychotics; HETEROAROMATIC-COMPOUNDS; ENZYME-INHIBITORS; BORON COMPOUNDS; B-N; SCHIZOPHRENIA; 2,1-BORAZARONAPHTHALENES; SUBSTITUTION; DERIVATIVES; CHEMISTRY; DISCOVERY;
D O I：
10.1016/j.bmc.2015.06.019
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The application of BN/CC isosterism is explored as a method of expanding the scope of core scaffolds in biologically active compounds. The viability of potential drug candidates incorporating BN-heteroaromatic moieties was investigated through the synthesis of BN-substituted analogs to known phosphodiesterase (PDE10A) inhibitors, namely MP10 and a selection of N-methylanilide analogs. These in some cases revealed unexpectedly potent and relatively stable derivatives, providing further support for the potential of BN-incorporation in medicinal chemistry. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码：4453 / 4461
页数：9
相关论文
共 50 条
  • [41] Rapid approach to identification of a PDE10A tracer to support development of PDE10A inhibitors in preclinical and clinical studies
    Harrington, Essa Hu
    Ma, Ji
    Biorn, Christopher
    Lester-Zeiner, Dianna
    Cho, Robert
    Rumfelt, Shannon
    Kunz, Roxanne
    Nixey, Thomas
    Michelsen, Klaus
    Miller, Silke
    Shi, Jianxia
    Della Puppa, Geraldine Hill
    Talreja, Santosh
    Able, Jessica
    Hwang, Dah-Ren
    Slifstein, Mark
    Easwaramoorthy, Balu
    Hitchcock, Stephen
    Porter, Amy
    Allen, Jennifer
    Immke, David
    Treanor, James
    Chen, Hang
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [42] PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia
    Kehler, Jan
    Nielsen, Jacob
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (02) : 137 - 150
  • [43] Pyrazoloquinolines as PDE10A inhibitors: Discovery of a tool compound
    McElroy, William T.
    Tan, Zheng
    Basu, Kallol
    Yang, Shu-Wei
    Smotryski, Jennifer
    Ho, Ginny D.
    Tulshian, Deen
    Greenlee, William J.
    Mullins, Deborra
    Guzzi, Mario
    Zhang, Xiaoping
    Bleickardt, Carina
    Hodgson, Robert
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (03) : 1335 - 1339
  • [44] Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
    Xie, Z
    Adamowicz, WO
    Eldred, WD
    Jakowski, AB
    Kleiman, RJ
    Morton, DG
    Stephenson, DT
    Strick, CA
    Williams, RD
    Menniti, FS
    NEUROSCIENCE, 2006, 139 (02) : 597 - 607
  • [45] Loss of PDE10A expression in patients with PDE10A and ADYC5 mutations
    Niccolini, F.
    Mencacci, N.
    Rabiner, E.
    Salpietro, V.
    Pagano, G.
    Balint, B.
    Houlden, H.
    Gunn, R.
    Wood, N.
    Bhatia, K.
    Politis, M.
    MOVEMENT DISORDERS, 2017, 32
  • [46] Cellular and subcellular localization of PDE10A, a striatal-specific phosphodiesterase
    Menniti, FS
    Ryan, AM
    Seeger, TF
    Stephenson, DT
    Xie, Z
    Eldred, WD
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 306 - 306
  • [47] PDE10A knockout mice: Behavioral characterization and effects of papaverine, a PDE10A inhibitor
    Siuciak, J
    Chapin, DS
    McCarthy, SA
    Harms, J
    Schmidt, CJ
    Shrikhande, A
    Wong, S
    Williams, R
    Menniti, F
    James, L
    Strick, C
    Stock, J
    McNeish, J
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 116 - 116
  • [48] Loss of PDE10A expression in patients with PDE10A and ADYC5 mutations
    Niccolini, F.
    Mencacci, N. E.
    Rabiner, E.
    Salpietro, V.
    Pagano, G.
    Balint, B.
    Houlden, H.
    Gunn, R.
    Wood, N. W.
    Bhatia, K. P.
    Politis, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 659 - 659
  • [49] Discovery of AMG 579, a novel phosphodiesterase 10 (PDE10A) inhibitor, as a potential treatment for schizophrenia
    Allen, Jennifer R.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [50] TARGETING PDE10A IN SCHIZOPHRENIA
    Hoefgen, N.
    Grunwald, C.
    Langen, B.
    DRUGS OF THE FUTURE, 2012, 37 (08) : 577 - 589
12345